Pharmaceutical products | Tenderlake

Pharmaceutical products

Contract Value:
GBP 199M -
Notice Type:
Contract Notice
Published Date:
08 February 2022
Closing Date:
16 March 2022
Location(s):
UK UNITED KINGDOM
UKD NORTH WEST (ENGLAND) (UK UNITED KINGDOM)
Description:
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema for a period of 18 months, with an option to extend up to 30 months.
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 1 – C1 Esterase – Recombinant IV (acute treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 6 - Lanadelumab

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 7 - Berotralstat

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 5 - Icatibant

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Download full details as .pdf
The Buyer:
The NHS Commissioning Board (operating under the name of NHS England)
CPV Code(s):
33141510 - Blood products
33141520 - Plasma extracts
33600000 - Pharmaceutical products